{"id":"nicotinic-acid-laropiprant","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing (reduced vs. niacin monotherapy)"},{"rate":null,"effect":"Hyperglycemia / elevated glucose"},{"rate":null,"effect":"Hyperuricemia / gout"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicotinic acid (niacin) is a B vitamin that activates lipid metabolism pathways to improve the cholesterol profile. Laropiprant is a selective antagonist of the GPR109A receptor, which mediates the uncomfortable flushing side effect caused by nicotinic acid alone, thereby improving tolerability and compliance.","oneSentence":"Nicotinic acid raises HDL cholesterol and lowers triglycerides and LDL cholesterol, while laropiprant blocks the niacin flush response by antagonizing the GPR109A receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:16.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia / mixed dyslipidemia in patients at risk of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT01274559","phase":"PHASE3","title":"Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1173},{"nctId":"NCT01308203","phase":"PHASE4","title":"Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Daniel A. Siniawski","startDate":"2011-10","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":32},{"nctId":"NCT01054508","phase":"PHASE4","title":"Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2010-06","conditions":"Hypercholesterolemia","enrollment":38},{"nctId":"NCT00769132","phase":"PHASE1","title":"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-03","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT01683656","phase":"PHASE4","title":"ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART","status":"TERMINATED","sponsor":"Calmy Alexandra","startDate":"2012-08","conditions":"HIV, Atherosclerosis","enrollment":4},{"nctId":"NCT01118598","phase":"PHASE4","title":"Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2010-06","conditions":"Polycystic Ovary Syndrome","enrollment":34},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":407},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00111891","phase":"PHASE2","title":"An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Dyslipidemia","enrollment":575},{"nctId":"NCT00376584","phase":"PHASE3","title":"Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesteremia, Hyperlipidemia","enrollment":825},{"nctId":"NCT00378833","phase":"PHASE3","title":"Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":1300},{"nctId":"NCT01052311","phase":"PHASE4","title":"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2010-07","conditions":"Coronary Artery Disease, Dyslipidemia","enrollment":8},{"nctId":"NCT01583647","phase":"PHASE1","title":"A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06","conditions":"Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00384293","phase":"PHASE3","title":"Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hypercholesterolemia, Familial","enrollment":937},{"nctId":"NCT00618995","phase":"PHASE1","title":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00536510","phase":"PHASE3","title":"Effect of MK0524A on Cholesterol Levels (0524A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":646},{"nctId":"NCT00536237","phase":"PHASE2","title":"MK0524A Phase IIb Study (0524A-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":"Flushing","enrollment":154},{"nctId":"NCT00269204","phase":"PHASE3","title":"Lipid Efficacy/Tolerability Study (0524A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Primary Hypercholesterolaemia, Mixed Hyperlipidaemia","enrollment":1620},{"nctId":"NCT00943124","phase":"PHASE1","title":"MK0524B Bioequivalence Study (0524B-070)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Dyslipidemia","enrollment":188},{"nctId":"NCT01414166","phase":"PHASE3","title":"Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":"Dyslipidemia","enrollment":244},{"nctId":"NCT01228019","phase":"","title":"Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-12","conditions":"Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1166},{"nctId":"NCT00664287","phase":"PHASE3","title":"Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00961636","phase":"PHASE3","title":"A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":1152},{"nctId":"NCT02153879","phase":"PHASE4","title":"Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment","status":"COMPLETED","sponsor":"Institut Investigacio Sanitaria Pere Virgili","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus, Dyslipidemia","enrollment":30},{"nctId":"NCT01239992","phase":"PHASE4","title":"Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia","status":"TERMINATED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2011-06","conditions":"Hyperlipoproteinemia, Metabolic Syndrome","enrollment":12},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT01942291","phase":"PHASE4","title":"Short-term Effect of Extended-release Niacin on Endothelial Function.","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2012-03","conditions":"Hypoalphalipoproteinemia","enrollment":18},{"nctId":"NCT01391377","phase":"NA","title":"Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Bayside Health","startDate":"2011-07","conditions":"Peripheral Arterial Disease","enrollment":7},{"nctId":"NCT01450410","phase":"PHASE4","title":"Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL","status":"TERMINATED","sponsor":"Xavier Pinto Sala","startDate":"2012-07","conditions":"Dyslipidemias","enrollment":12},{"nctId":"NCT01321034","phase":"PHASE4","title":"Effect of Niacin in the Lipoprotein (a) Concentration","status":"COMPLETED","sponsor":"Instituto Aragones de Ciencias de la Salud","startDate":"2011-10","conditions":"Hypercholesterolemia","enrollment":90},{"nctId":"NCT01126073","phase":"PHASE4","title":"Niacin/Laropiprant and Endothelial Function","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2010-09","conditions":"Coronary Heart Disease","enrollment":60},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120},{"nctId":"NCT01071525","phase":"PHASE3","title":"The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2010-04","conditions":"Hypercholesterolemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL DISCOMFORT"},{"count":1,"reaction":"ACUTE ABDOMEN"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DERMATITIS ALLERGIC"},{"count":1,"reaction":"FLUSHING"},{"count":1,"reaction":"SMALL INTESTINAL PERFORATION"},{"count":1,"reaction":"TREATMENT NONCOMPLIANCE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tredaptive"],"phase":"marketed","status":"active","brandName":"nicotinic acid/laropiprant","genericName":"nicotinic acid/laropiprant","companyName":"Manchester University NHS Foundation Trust","companyId":"manchester-university-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Niacin/laropiprant is being studied for its potential effects on conditions such as coronary heart disease, hypercholesteremia, hyperlipidemia, and hypercholesterolemia. The exact mechanism of action of niacin/laropiprant is not specified, but it is known to be a combination of nicotinic acid and laropiprant, which is a prostaglandin D2 receptor antagonist.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}